Sign In
Buy HSDT
$1.51
-0.120 (-7.36%)
At Close: Jun 23, 2026
Helius Medical Technologies, Inc. Compliant with Nasdaq's Continued Listing Requirements
08:30am, Wednesday, 09'th Jul 2025
NEWTOWN, Pa., July 09, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neur
Helius Medical Technologies, Sunrun And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
08:01am, Tuesday, 08'th Jul 2025
U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Tuesday.
Helius Medical Technologies Announces Reverse Stock Split
08:30am, Friday, 27'th Jun 2025
NEWTOWN, Pa., June 27, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuro
- CignaHealth becomes fifth major payer to authorize claim for PoNS Device at out-of-network adjusted negotiated list price of $19,161- -This follows another recent authorization by Anthem Multiplan f
Positive PoNSTEP Study Results Presented at Consortium of Multiple Sclerosis Centers Annual Meeting
07:00am, Thursday, 12'th Jun 2025
-PoNS Therapeutic Experience Program (PoNSTEP) study demonstrates durable long-term beneficial effects of PoNS Therapy® on gait deficit improvement in people with Multiple Sclerosis-
-Aetna authorizes claim for PoNS Device at out-of-network negotiated price of $18,350, becoming the third payer to join Anthem and United in providing PoNS reimbursement-
Helius Medical Technologies Announces Pricing of $9.1 Million Public Offering
09:12pm, Wednesday, 04'th Jun 2025
NEWTOWN, Pa., June 04, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neur
Helius Medical Technologies, Inc. Compliant with Nasdaq Bid Price Rule Listing Criteria
07:00am, Wednesday, 04'th Jun 2025
Company previously granted extension until June 30, 2025 to regain compliance with Nasdaq's Equity Rule requirement Company previously granted extension until June 30, 2025 to regain compliance with N
Helius to Spotlight Study Confirming Improved Long-Term Outcomes from Adherence to PoNS Therapy® at CMSC Annual Meeting
07:00am, Tuesday, 20'th May 2025
Shepherd Center's Dr. Deborah Backus to Showcase Final Results of PoNSTEP Study, Providing New Insight into Maximizing Impact of Neuromodulation to Improve Gait in People with MS Shepherd Center's Dr.
United Healthcare approves claim for PoNS Device at out-of-network adjusted list price, becoming the second payer to join Anthem in providing PoNS reimbursement United Healthcare approves claim for Po
Helius Medical Technologies Announces Reverse Stock Split
09:00am, Wednesday, 30'th Apr 2025
NEWTOWN, Pa., April 30, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neur
--Revelation Neuro, Inc. is focused on advancing development of a Non-Implantable Artificial Intelligence (“AI”) Powered BCI Technology-- --Helius' existing IP portfolio and extensive data warehou
--Anthem Blue Cross Blue Shield approves claim for PoNS Device at out-of-network adjusted list price-- --Provides further validation of PoNS pricing-- NEWTOWN, Pa., March 11, 2025 (GLOBE NEWSWIRE) --
--PoNS Therapeutic Experience Program (PoNSTEP) study demonstrates durable long-term beneficial effects of PoNS Therapy on gait deficit improvement in people with Multiple Sclerosis-- --Statistically
NEWTOWN, Pa., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuro
